Acurx Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
31.0%projected annual EPS growth
Analyst Coverage
3analysts covering
FY EPS (est.)
-$1.97next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash Balance Quarterly9.3MTarget: Sufficient capital to fund Phase 3 clinical trials
Clinical Cure Rate (ibezapolstat Phase 2) Annually96.0%Target: Maintain high efficacy in Phase 3 trials
Recurrence Rate in Cured Patients (ibezapolstat Phase 2) Annually0.0%
Watch Items
- Initiation of the open-label pilot trial for recurrent C. difficile infection (rCDI)Trigger: First patient enrollment expected in H2 2026Action: Monitor clinical trial registry updates and company press releases for enrollment milestones.
- Funding and liquidity for international Phase 3 trialsTrigger: Cash runway and utilization of the Lincoln Park equity line of credit (ELOC)Action: Review quarterly 10-Q filings for cash burn rate and capital raising activities.
- FDA guidance on single-trial registration pathwayTrigger: Formalization of the one-trial standard for CDI registrationAction: Track regulatory announcements and corporate updates regarding Phase 3 trial design adjustments.
Research as of 20 Jun 2026